No. of patients (%)
|
67 (100)
|
15 (22.4)
|
2 (3.0)
|
15 (22.4)
|
34 (50.7)
|
1 (1.5)
|
Male gender (%)
|
33 (49.3)
|
10 (66.7)
|
2 (100)
|
7 (46.7%)
|
13 (38.2%)
|
1 (100)
|
Mean age at time of first isolation of VIM-PA (range, SD)
|
56.6 (18–82, 14.2)
|
53.0 (20–71, 13.3)
|
46.1 (40–52, 9.0)
|
58.3 (34–82, 12.6)
|
57.5 (18–80, 15.1)
|
79.1
|
Mean age at time of death (range, SD)
|
57.0 (18–82, 14.0)
|
53.3 (20–71, 13.5)
|
46.3 (40–53, 8.8)
|
58.8 (37–82, 11.8)
|
57.8 (18–81, 15.0)
|
79.1
|
Median LOS before first VIM-PA culture, days, (range)
|
23 (0–244)
|
22 (1–244)
|
85 (80–90)
|
37 (4–126)
|
22 (0–202)
|
0
|
28-day mortality (%)
|
36 (53.7)
|
11 (73.3)
|
0 (0)
|
7 (46.7)
|
17 (50.0)
|
1 (100)
|
1-year mortality (%)
|
61 (91.0)
|
14 (93.3)
|
2 (100)
|
14 (93.3)
|
30 (88.2)
|
1 (100)
|
Location of first VIM-PA; ICU (%)
|
49 (73.1)
|
13 (86.7)
|
0 (0)
|
13 (86.7)
|
23 (67.6)
|
0 (0)
|
Ward of acquisition; ICU (%)
|
47 (70.1)
|
13 (86.7)
|
0 (0)
|
12 (80.0)
|
22 (64.7)
|
0 (0)
|
Location of death; ICU (%)
|
43 (64.2)
|
14 (93.3)
|
1 (50.0)
|
9 (60.0)
|
19 (55.9)
|
0 (0)
|
Nosocomial acquisition
|
67 (100)
|
15 (100)
|
2 (100)
|
15 (100)
|
34 (100)
|
1 (100)
|
Source of infection
|
Pneumonia (%)
|
15 (22.4)
|
7 (46.7)
|
1 (50.0)
|
7 (46.7)
|
0 (0)
|
0 (0)
|
Gastro-intestinal (%)
|
11 (16.4)
|
4 (26.7)
|
1 (50.0)
|
6 (40.0)
|
0 (0)
|
0 (0)
|
Pneumonia and/or gastro-intestinal (%)
|
2 (3.0)
|
1 (6.7)
|
0 (0)
|
1 (6.7)
|
0 (0)
|
0 (0)
|
Pneumonia and/or skin and soft tissue (%)
|
2 (3.0)
|
2 (13.3)
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
Gastro-intestinal and/or cardiovascular system (%)
|
1 (1.5)
|
0 (0)
|
0 (0)
|
1 (6.7)
|
0 (0)
|
0 (0)
|
Gastro-intestinal and/or skin and soft tissue (%)
|
1 (1.5)
|
1 (6.7)
|
0 (0)
|
0 (0)
|
0 (0)
|
0 (0)
|
No infection or undetermined (%)
|
35 (52.2)
|
0 (0)
|
0 (0)
|
0 (0)
|
34 (100)
|
1 (100)
|
Charlson comorbidity scorea
|
Median Charlson score (range)
|
3 (0–9)b
|
2 (0–6)c
|
0.5 (0–1)
|
2 (0–5)
|
4 (1–9)d
|
4
|